The American Journal of Surgery
Volume 195, Issue 3 , Pages 318-321 , March 2008

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

  • Kimberly M. Brown, M.D.

      Affiliations

    • Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    • ,
  • Veeriah Siripurapu, M.D.

      Affiliations

    • Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    • ,
  • Marson Davidson, M.D.

      Affiliations

    • Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    • ,
  • Steven J. Cohen, M.D.

      Affiliations

    • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Andre Konski, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • James C. Watson, M.D.

      Affiliations

    • Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    • ,
  • Tiaynu Li, M.S.

      Affiliations

    • Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Vince Ciocca, M.D.

      Affiliations

    • Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Harry Cooper, M.D.

      Affiliations

    • Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • John P. Hoffman, M.D.

      Affiliations

    • Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    • Corresponding Author InformationCorresponding author. Tel. +1-215-728-3095; fax: +1-215-728-2773.

Received 15 November 2007 ,Revised 11 December 2007

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Kalser MH, Ellenberg SS. Pancreatic cancer (Adjuvant combined radiation and chemotherapy following curative resection). Arch Surg. 1985;120:899–903
  3. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival (A prospective, single-institution experience). Ann Surg. 1997;225:621–633
  4. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928–937
  5. Pendurthi TK, Hoffman JP, Ross E, et al. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg. 1998;64:686–692
  6. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65:618–623
  7. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121–130
  8. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234:758–768
  9. Sasson AR, Wetherington RW, Hoffman JP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34:121–128
  10. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–1046
  11. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766–772
  12. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951–955discussion 955–6
  13. Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195–199
  14. Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644–649
  15. Talamonti MS, Small W, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150–158
  16. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–331

PII: S0002-9610(07)00986-5

doi: 10.1016/j.amjsurg.2007.12.017

The American Journal of Surgery
Volume 195, Issue 3 , Pages 318-321 , March 2008

Article Tools

* Image Usage & Resolution